107 related articles for article (PubMed ID: 7757315)
1. Platelet aggregation after naftidrofuryl application in vitro and ex vivo.
Kirsten R; Erdeg B; Moxter D; Hesse K; Breidert M; Nelson K
Int J Clin Pharmacol Ther; 1995 Feb; 33(2):81-4. PubMed ID: 7757315
[TBL] [Abstract][Full Text] [Related]
2. Effect of naftidrofuryl on platelet aggregation in plasma from aspirin treated patients: an in vitro study.
Le Dévéhat C; Khodabandehlou T; Mosnier M
Clin Hemorheol Microcirc; 2000; 22(3):197-204. PubMed ID: 10976713
[TBL] [Abstract][Full Text] [Related]
3. Influence of naftidrofuryl, a serotonergic antagonist, on erythrocyte aggregation.
Nordt FJ; Jack W; Coull BM
J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S29-32. PubMed ID: 1369714
[TBL] [Abstract][Full Text] [Related]
4. Effects of urapidil on 5-hydroxytryptamine induced platelet aggregation and on 14C-5-hydroxytryptamine uptake in platelets.
Storck J; Ochs JG; Kirsten R
Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):303-8. PubMed ID: 2387654
[TBL] [Abstract][Full Text] [Related]
5. Effect of naftidrofuryl and aspirin on platelet aggregation in peripheral vascular disease.
Barradas MA; Stansby G; Hamilton G; Mikhailidis DP
In Vivo; 1993; 7(6A):543-8. PubMed ID: 8193274
[TBL] [Abstract][Full Text] [Related]
6. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.
Asai F; Jakubowski JA; Naganuma H; Brandt JT; Matsushima N; Hirota T; Freestone S; Winters KJ
Platelets; 2006 Jun; 17(4):209-17. PubMed ID: 16769598
[TBL] [Abstract][Full Text] [Related]
7. Serotonin, 5-HT2 receptors, and their blockade by naftidrofuryl: a targeted therapy of vascular diseases.
Wiernsperger NF
J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S37-43. PubMed ID: 7517475
[TBL] [Abstract][Full Text] [Related]
8. Influence of age on the pharmacokinetics of naftidrofuryl after single oral administration in elderly versus young healthy volunteers.
Hulot T; Gamand S; Dupain T; Ahtoy P; Bromet M
Arzneimittelforschung; 1998 Sep; 48(9):900-4. PubMed ID: 9793615
[TBL] [Abstract][Full Text] [Related]
9. Effect of naftidrofuryl on platelet-induced vasospasm in vitro. Role of antiserotonergic actions.
Verheggen R; Schrör K
Arzneimittelforschung; 1993 Mar; 43(3):330-4. PubMed ID: 8489562
[TBL] [Abstract][Full Text] [Related]
10. Carmoxirole inhibits platelet aggregation in vitro and ex vivo.
Kirsten R; Breidert M; Sparwasser K; Ochs JG; Hesse K; Nelson K
Int J Clin Pharmacol Ther; 1995 Feb; 33(2):76-80. PubMed ID: 7757314
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of the spasmogenic effect of exogenous and endogenous serotonin on isolated blood vessels by naftidrofuryl].
Verheggen R; Schrör K
Vasa Suppl; 1988; 24():5-10. PubMed ID: 3212604
[No Abstract] [Full Text] [Related]
12. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
Shaw LA; Batey AJ; Coker SJ
Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
[TBL] [Abstract][Full Text] [Related]
13. The effect of naftidrofuryl, a 5-HT2 antagonist, on collateral vascular responses to serotonin and to platelet activation.
Hollenberg NK; Nie Q
J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S36-9. PubMed ID: 1369716
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of the efficacy and tolerance of naftidrofuryl in patients presenting with exertional angina. Multicenter double-blind versus placebo study].
Hirsch JL; Bensoussan JJ; Mosnier M; Lehert P
Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):137-45. PubMed ID: 12555338
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of constriction of cerebral arterioles in vivo by naftidrofuryl. Action against serotonin and dinoprost.
Rosenblum WI
Arzneimittelforschung; 1987 May; 37(5):495-7. PubMed ID: 3476118
[TBL] [Abstract][Full Text] [Related]
16. 5-Hydroxytryptamine-2A receptor gene (HTR 2 A) candidate polymorphism (T 102 C): Role for human platelet function under pharmacological challenge ex vivo.
Ozdener F; Gülbas Z; Erol K; Ozdemir V
Methods Find Exp Clin Pharmacol; 2005; 27(6):395-400. PubMed ID: 16179957
[TBL] [Abstract][Full Text] [Related]
17. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
Uchiyama S; Ozaki Y; Satoh K; Kondo K; Nishimaru K
Cerebrovasc Dis; 2007; 24(2-3):264-70. PubMed ID: 17622759
[TBL] [Abstract][Full Text] [Related]
18. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.
Matsushima N; Jakubowski JA; Asai F; Naganuma H; Brandt JT; Hirota T; Freestone S; Winters KJ
Platelets; 2006 Jun; 17(4):218-26. PubMed ID: 16769599
[TBL] [Abstract][Full Text] [Related]
19. Effects of garlic oil on platelet aggregation: a double-blind placebo-controlled crossover study.
Wojcikowski K; Myers S; Brooks L
Platelets; 2007 Feb; 18(1):29-34. PubMed ID: 17365851
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects.
Savcic M; Hauert J; Bachmann F; Wyld PJ; Geudelin B; Cariou R
Semin Thromb Hemost; 1999; 25 Suppl 2():15-9. PubMed ID: 10440417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
